Nanobiosym Chairman and CEO Awarded Top Prize in Galactic Grant Competition

Nanobiosym®, a global nanotechnology firm, today announced that its Chairman and CEO, Dr. Anita Goel, M.D., Ph.D, has been awarded the top prize in the Galactic Grant Competition to fund the Nanobiosym Research Institute to push the frontier of nanobiophysics and the Gene-RADAR® technology on the International Space Station (ISS), U.S. National Laboratory.

Uniquely trained as both a physicist and medical doctor at Stanford, Harvard, and MIT, Dr. Goel has, over the past 20 years, pioneered and established through her Nanobiosym Research Institute, a new science at the convergence of Physics, Biomedicine, Nanotechnology and Information Communications Technology. From this science Dr. Goel has developed a commercial product called Gene-RADAR®, a mobile tricorder-like device that enables gold standard real-time diagnosis of any disease with a genetic fingerprint. Gene-RADAR® recently won the prestigious XPRIZE - an international competition that recognizes breakthrough technologies that benefit humanity on an exponential scale.

“I am delighted to accept this award and launch this pivotal partnership between Nanobiosym and the ISS to develop new ‘apps’ for our Gene-RADAR® technology,” said Dr. Goel. “The microgravity environment on the ISS makes biological organisms mutate faster. Gene- RADAR® on the ISS will help us better predict how deadly pathogens here on Earth can mutate to become drug-resistant superbugs, such as MRSA. Our ability to anticipate drug-resistant mutations with Gene-RADAR® will lead to next generation antibiotics that are more precisely tailored to stop the spread of the world’s most dangerous pathogens. We will leverage our research on the ISS to accelerate the Precision Medicine revolution here on Earth.”

Massachusetts Governor Charlie Baker joined leaders from NASA, the Center for the Advancement of Science in Space (CASIS) and the Massachusetts Life Sciences Center (MLSC) to present the Galactic Grant award to Dr. Goel, Tuesday, July 7, 2015 as part of the ISS Research & Development Conference taking place in Boston this week.

“Collaboration is one of our greatest strengths in Massachusetts, and through this first-ever collaboration between CASIS and the MLSC local companies have had the unique opportunity to compete for funds to support innovative life sciences experiments on the International Space Station,” said Governor Charlie Baker. “Congratulations to the winners of this competition, and I look forward to seeing the results of this important research.”

Dr. Goel is also a featured speaker at this conference alongside other innovators who are pushing the frontier of Space Research to improve life on Earth such as SpaceX and Tesla CEO Elon Musk, other premier scientists, and three active NASA astronauts.

According to global experts, drug-resistant infections, if they are not tackled could kill an extra 10 million people every year by 2050 and cost the global economy at least $100 trillion in lost output.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanobiosym. (2019, February 11). Nanobiosym Chairman and CEO Awarded Top Prize in Galactic Grant Competition. AZoNano. Retrieved on June 20, 2024 from

  • MLA

    Nanobiosym. "Nanobiosym Chairman and CEO Awarded Top Prize in Galactic Grant Competition". AZoNano. 20 June 2024. <>.

  • Chicago

    Nanobiosym. "Nanobiosym Chairman and CEO Awarded Top Prize in Galactic Grant Competition". AZoNano. (accessed June 20, 2024).

  • Harvard

    Nanobiosym. 2019. Nanobiosym Chairman and CEO Awarded Top Prize in Galactic Grant Competition. AZoNano, viewed 20 June 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.